# C_2017128EN.01000401.xml

| 22.4.2017 | EN | Official Journal of the European Union | C 128/4 |
| --- | --- | --- | --- |

22.4.2017

EN

Official Journal of the European Union

C 128/4

---

Prior notification of a concentration

(Case M.8401 — Johnson & Johnson/Actelion)

(Text with EEA relevance)

(2017/C 128/03)

| 1. | On 12 April 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Johnson & Johnson, (‘J&J’, USA) through Janssen Holding GmbH (‘Janssen’, Switzerland), acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Actelion Pharmaceuticals Ltd (‘Actelion’, Switzerland) by way of purchase of shares. |
| --- | --- |

1.

On 12 April 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Johnson & Johnson, (‘J&J’, USA) through Janssen Holding GmbH (‘Janssen’, Switzerland), acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Actelion Pharmaceuticals Ltd (‘Actelion’, Switzerland) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   for J&J: active in the business sectors of consumer goods, pharmaceuticals and medical devices. Janssen, a subsidiary of J&J, is dedicated to the pharmaceutical business sector,
  —   for Actelion: active in the prescription pharmaceutical sector and specialised in the research and development of specialty in-market medicines and late-stage products related to a number of therapeutic areas (including, most notably, pulmonary arterial hypertension). |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for J&J: active in the business sectors of consumer goods, pharmaceuticals and medical devices. Janssen, a subsidiary of J&J, is dedicated to the pharmaceutical business sector,

for J&J

—   for Actelion: active in the prescription pharmaceutical sector and specialised in the research and development of specialty in-market medicines and late-stage products related to a number of therapeutic areas (including, most notably, pulmonary arterial hypertension).

for Actelion

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8401 — Johnson&Johnson/Actelion, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8401 — Johnson&Johnson/Actelion, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---